News

Measuring how often a person spontaneously blinks could help predict motor changes in people with Parkinson’s disease being treated with levodopa, a study suggests. The study, “Using Spontaneous Eye-blink Rates to Predict the Motor Status of Patients with Parkinson’s Disease,” was published in the journal Internal…

One amino acid change in the brain-derived neurotrophic factor (BDNF) gene, which provides instructions for a protein important to neuronal survival, may be associated with cognitive impairment in Parkinson’s disease patients, a study has found. The study, “BDNF Val66Met polymorphism and cognitive impairment in Parkinson’s…

Gocovri (amantadine) can effectively reduce the number and duration of “off” periods and dyskinesia (uncontrolled movement) episodes in Parkinson’s patients under long-term levodopa treatment, leading to a good steady “on” state, pooled Phase 3 clinical data show. These findings were reported in a study, “…

Positive preclinical and Phase 1 clinical data support further assessment of Aptinyx‘s investigational compound NYX-458 for the treatment of cognitive impairment associated with Parkinson’s disease in new Phase 2 studies. Aptinyx expects to launch a new Phase 2 clinical study in Parkinson’s patients this year, the company…

Intensive singing interventions have the potential to increase vocal loudness, respiratory muscle strength, and voice-related quality of life in people with Parkinson’s disease, a study suggests. The study, “ParkinSong: A Controlled Trial of Singing-Based Therapy for Parkinson’s Disease,” was published…

Treatment with standard Parkinson’s therapies, such as levodopa or dopamine agonists, can provide effective relief of central parkinsonian pain, but they may fail to manage motor symptoms in these patients, a study has found. As many patients with Parkinson’s disease…

Abbott is partnering with the National Institutes of Health (NIH) to explore the use of its neuromodulation technologies for treating chronic pain and progressive movement disorders, including Parkinson’s disease. The partnership’s goal is to drive forward the Brain Research through Advancing Innovative Neurotechnologies initiative, known as…

PatientPoint, in collaboration with five U.S. patient advocacy organizations, has introduced a technology-driven point-of-care network for neurologists, neurology patients, and caregivers. With a focus on neurological conditions such as Parkinson’s and Alzheimer’s disease, the comprehensive network hopes to promote improved communication between patients and physicians. The new patient…

Mutations in the LRRK2 gene, which have been linked to familial Parkinson’s disease, impair the activity of the waste clearance system inside nervous brain cells, contributing to their progressive degeneration, a study finds. Using a compound called clioquinol, researchers could restore the activity of lysosomes — the…

Almost half of people in the early stages of Parkinson’s disease already have signs of neurodegeneration in a brain region called the caudate, which was previously thought to affect mostly those at advanced disease stages, a study reports. Early caudate involvement on both…